Berlin Cures beruft renowned Immunologists Professor Danny Altmann in Berategremium

Issuer / Name: Berlin Cures Holding AG / Shareholder: Personal/Research Update

Berlin Cures beruft renowned Immunologists Professor Danny Altmann in Berategremium

29.08.2024 / 08:00 CET/CEST
Inhaling the Mitteilung is the Issuer / Herausgeber responsible.

Berlin, Germany, August 29, 2024 – Berlin Cures, a biotechnology company in clinical phase II for a drug against long COVID, where the commotion of Professor Danny Altmann in his doctoral committee is known. Altmann, appointed immunologist at Imperial College London, has extensive expertise in the field of internal medicine, which focuses on autoimmune diseases that have undergone another long COVID treatment. The committee recommends Berlin Cures from branch development and new tumor sites and would provide the following market entry new therapies.

“Wir friends are welcome, Professor Altmann will come back soon”, says Oliver von Stein, CEO of Berlin Cures. “If there is a warning and the treatment is in immunology, be careful with the long term of SARS-CoV-2 infections, so that you can find the ideal treatment for the disease. If you have a good overview, you can get a greater insight into our best treatments see wird, effective treatments for Long COVID and other diseases with functional autoantibodies associated with each other on the market to bring.”

Danny Altmann is Professor of Immunology at Imperial College London, based at Labor on the Hammersmith Hospital campus. As Altmann’s war on the COVID-19 pandemic is being eradicated, so too is the political and organizational divisions that are being eradicated, bringing to light the scientific silos of the House of Commons and the House of Lords, the EU, the Scottish Parliament, the Weltgesundheitsorganization, and many more. This article is a long-term immunological study of SARS-CoV-2 infections. Zudem is the supporter of the UK organization Long COVID Support and co-author of Penguin Long COVID handbooks.

Berlin Cures, a biotechnology company, which is the neutralization function of an autoantibiotic specialist, is conducting a phase II clinical trial with functional candidates BC 007 (Rovunaptabin) in patients with long COVID duration. First results were reported in the fourth quarter of 2024. The study has completed a phase IIa study with BC 007 by the recovery, which performed a long neutralization of the functional autoantibiotics on a malignant Gabe.

Berlin Cures is active in the field of financing partners, a possible Phase III study is made possible after a positive development of Phase II to realize. A Phase III study has been performed which was carried out for a market study of BC 007 dar.

Short biographies of Danny Altmann and other information about the available beratergremiums here.

About Berlin cures:
The Berlin Cures team has spent more time studying the functioning of autoantibiotics (fAAKs) and has identified a molecule that effectively neutralizes. There are many different practical results for BC 007. In a phase IIa study in patients with long-term rearrangement, BC 007 was able to achieve long-lasting neutralization of the autoantibiotics after a single dose. It was possible that we would investigate a meaningful treatment of heart function with BC 007. The potential of BC 007 as the same therapy had known a long COVID period, while Seren of long-COVID patients tested positive for fAAKs, was supported during four fall studies during clinical studies. Indem Berlin Cures mit die single Biotechnologie die Ursache van faak-associatie-associatie-krankheiten bekämpft, leistet das Unternehmen Pionierarbeit, een zu die zwerwiegende Gesundheitsproblem grundlegende zu addresssieren.

Berlin Cures has initiated a Phase II clinical study with BC 007 in the indication long COVID-19, a global problem, allowing for extensive and burdensome problem-solving experience. First results were reported in Q4 2024.

Contact:
FGS Worldwide
Email address: [email protected]

Veröffentlichung und Mitteilung, übermittelt von EQS Group AG.
Media archive under https://www.eqs-news.com.

Inhaling the Mitteilung is the Issuer / Herausgeber responsible.